Publicaciones en colaboración con investigadores/as de Hospital Clínico San Carlos de Madrid (4)

2024

  1. Predictors of unsustained measurable residual disease negativity in transplant-eligible patients with multiple myeloma

    Blood, Vol. 143, Núm. 7, pp. 597-603

2021

  1. Genomic mutation profile in progressive chronic lymphocytic leukemia patients prior to first-line chemoimmunotherapy with FCR and rituximab maintenance (REM)

    PLoS ONE, Vol. 16, Núm. 9 September

  2. Pomalidomide, Cyclophosphamide, and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma: Real-World Analysis of the Pethema-GEM Experience

    Clinical Lymphoma, Myeloma and Leukemia, Vol. 21, Núm. 6, pp. 413-420

2020

  1. Safety of switching from intravenous to subcutaneous rituximab during first-line treatment of patients with non-Hodgkin lymphoma: the Spanish population of the MabRella study

    British Journal of Haematology, Vol. 188, Núm. 5, pp. 661-673